Navigating an Increasingly Complex Treatment Paradigm in the Management of Breast Cancer: Optimizing Clinical and Economic Outcomes with Targeted Therapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2023, to March 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme LLC

Description:
Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2022. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer
(MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with both early and advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of breast cancer, including factors that contribute to poor prognosis and increased costs

  • Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer

  • Explore recent efficacy and safety data on current and emerging PARP inhibitors for the treatment of both early and advanced breast cancer

  • Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing

  • Evaluate strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies in breast cancer

  • Discuss the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into current advanced breast cancer management paradigm

     

Faculty: Heather McArthur, MD, MPH
Clinical Director of Breast Oncology
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. McArthur has served on an advisory board for AstraZeneca, Bristol Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead, Immunomedics, Lilly, Merck, Puma Biotechnology, and Seagen. She has received grant/research support from AstraZeneca and Merck. Her presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme LLC


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue